A set of AstraZeneca antibodies will save those who cannot be vaccinated from covid

AstraZeneca has announced that applications have been submitted in different countries for the registration of a new type of drug from SARS-CoV-2 called AZD7442. It was created on the basis of antibodies collected from the first patients with COVID-19 a year and a half ago. With their help, effective monoclonal antibodies were obtained, which have already passed clinical trials.Attention to antibody treatment arose against the background of the failed vaccination situation both in the world as a whole and in individual countries.

It turned out that humanity will not be able to achieve collective immunity in principle because of the many differences of political, social, religious and other kinds. But even worse, there are a number of patients with chronic diseases, extremely low immunity and undergoing immunosuppressive treatment for other diseases – their body will not withstand contact with the vaccine. In the AZD7442 trial, called Provent, 5,000 immunocompromised patients were monitored for six months. No cases of severe course of the disease were detected, although many people were infected with covid.

According to the results of the test, it was concluded that AZD7442 reduces the risk of developing symptomatic COVID-19 by 77 %. Antibodies do not heal people, but they take over most of the fight against the virus, as a result of which the disease proceeds in a mild form. This is a long-awaited chance for people with weakened immune systems to get protection from infection.